Schulzer, M <br/><br/>
The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.  [electronic resource] 

 -  Annals of neurology  Dec 1992 
 - 795-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0364-5134 
<br/><br/><label>Standard No.: </label>10.1002/ana.410320614  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Humans<br/>Models, Statistical<br/>Parkinson Disease--drug therapy<br/>Selegiline--therapeutic use<br/>Survival Analysis